LifeBond to present LifeMesh self-fixating hernia mesh platform at MIXiii Biomed Conference

Embedded Adhesive, Activated by Tissue Contact, is Biomaterial Technology Breakthrough

LifeBond Ltd., a leading developer of absorbable biosurgical products for tissue repair, announced today its new self-fixating hernia mesh platform, LifeMesh™, which will be presented at the upcoming MIXiii Biomed Conference, to be held at the Israel Convention Center in Tel Aviv on May 20-22. LifeMesh™ is being developed to provide strong, atraumatic fixation of prosthetic mesh for reinforcement of tissue during surgical repair of abdominal wall defects. The self-fixating surgical mesh is being developed to simplify hernia repair and reduce the complications associated with penetrative mesh fixation using tacks or sutures.

LifeMesh™ mesh fixation has the potential to be implemented in both inguinal and ventral hernia repairs, either in laparoscopic or open approach. There are approximately 1M such procedures every year, 850k Inguinal and 150K ventral, in the US alone. The embedded adhesive production process provides the technology to transform nearly any commercial mesh into a self-fixating mesh, thus facilitating great clinical impact across a range of hernia types.

"The successful expansion into a second, non-dependent product platform is a great achievement for our company,” said Gideon Sturlesi, CEO of LifeBond. “Following clinical deployment of our first product, LifeSeal™ Surgical Sealant, LifeBond is now poised to rapidly realize additional products in our next-generation surgical toolbox pipeline.”